Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.

Domperidone 30–80 mg daily safe for treatment of gastroparesis

05 Oct 2019

The association between domperidone at commonly prescribed doses of 30–80 mg/d and QTc prolongation is observed in only 6 percent of patients, with no case of QT interval reaching the point considered to be clinically significant, reports a study.

This finding suggests that domperidone can be safely prescribed at conventional doses for the treatment of gastroparesis, according to the authors.

Patients who received domperidone for gastroparesis between January 2012 and September 2017 at a single centre were included in the analysis. Electrocardiograms (ECGs), primarily the QTc interval, taken at baseline, 2–6 months after initiation of domperidone, 6–12 months after initiation and ≥12 months after initiation were reviewed. Concurrent QTc prolonging medications were recorded for each patient.

The primary endpoint was QTc prolongation >500 ms, while secondary ones were QTc >450 ms for males, QTc >470 ms for females, QTc prolongation ≥20 ms above baseline and QTc prolongation >60 ms above baseline.

A total of 246 patients (mean age, 46.3 years; 209 females) were analysed. ECGs were available for all 246 patients prior to treatment, for 170 at 2–6 months, for 135 at 6–12 months and for 152 at least 1 year following initiation of domperidone.

Clinically important QTc prolongation occurred in 15 patients (6.1 percent; 9 females), of whom 11 had QTc >450 ms for males or >470 ms for females. None of them had QTc prolongation >500 ms. Five patients (2.0 percent) had >60 ms over baseline, and 61 (24.7 percent) had QTc increase of ≥20 ms but <60 ms from baseline.

“Domperidone is a dopamine receptor antagonist used for the treatment of gastroparesis,” the authors noted. “However, it has been associated with QT prolongation, ventricular arrhythmias and sudden cardiac death.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.